Print（PDF/195KB） Jun. 20, 2023 Corporate
Sumitomo Pharma Announces Change in Name of Wholly Owned Subsidiary Companies
Sumitomo Pharma Co., Ltd. (the “Company”) (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that on June 19, 2023 (local time), it decided to change the names of its wholly owned subsidiary companies in connection with the combination announced in the press release dated April 3, 2023, entitled “Sumitomo Pharma Announces the Combination of Group Companies in the U.S.,” as described below.
1．Details Regarding the Change of Company Names
The name of the remaining company after the combination of Group companies in the U.S. will be changed from Sunovion Pharmaceuticals Inc. to Sumitomo Pharma America, Inc. The name of the UK holding company will be changed from Sumitovant Biopharma Ltd. to Sumitomo Pharma UK Holdings, Ltd.
2．Reason for the Change
On the occasion of the combination of its Group companies in the U.S., the Company has decided to change the names of the two companies to unify the corporate brand as one of the Group companies.
3. Date of the Change
July 1, 2023
4．Overview of Sunovion Pharmaceuticals Inc. and Sumitovant Biopharma Ltd.
(1) Sunovion Pharmaceuticals Inc.
| Company Name | Sunovion Pharmaceuticals Inc. |
| Head Office | Marlborough, MA, U.S.A. |
| Representative | Antony Loebel, President and Chief Executive Officer |
| Description of Business | Manufacturing and sale of pharmaceuticals |
| Capital | US$0.01 |
| Date of Establishment | January 1984 |
| Major Shareholder and Shareholding Ratio | Sumitomo Pharma America Holdings, Inc. 100% (100% sub-subsidiary of Sumitomo Pharma Co., Ltd.) |
（2） Sumitovant Biopharma Ltd.
| Company Name | Sumitovant Biopharma Ltd. |
| Head Office | London, UK |
| Representative | Monika Adams, Transactions Officer |
| Description of Business | Holding company, management of Sumitovant group companies and formulation and promotion of business strategies, etc. |
| Capital | US$2,000 |
| Date of Establishment | October 2019 |
| Major Shareholder and Shareholding Ratio | 100% subsidiary of Sumitomo Pharma Co., Ltd. |
- ＊ For the press release dated April 3, 2023, entitled “Sumitomo Pharma Announces the Combination of Group Companies in the U.S.,” please see below.
- https://www.sumitomo-pharma.com/news/20230403.html
Inquiries from the Press